financetom
Business
financetom
/
Business
/
Shake Shack Insider Sold Shares Worth $1,102,403, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shake Shack Insider Sold Shares Worth $1,102,403, According to a Recent SEC Filing
Aug 19, 2024 3:08 PM

05:56 PM EDT, 08/19/2024 (MT Newswires) -- Daniel Harris Meyer, 10% Owner, Director, on August 15, 2024, sold 10,000 shares in Shake Shack ( SHAK ) for $1,102,403. Following the Form 4 filing with the SEC, Meyer has control over a total of 1,778,701 shares of the company, with 2,958 shares held directly and 1,775,743 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1620533/000162053324000093/xslF345X03/wk-form4_1724104017.xml

Price: 105.11, Change: +0.42, Percent Change: +0.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enovix Wins Contract to Provide Silicon Batteries for Mixed Reality Headsets
Enovix Wins Contract to Provide Silicon Batteries for Mixed Reality Headsets
Jun 25, 2024
07:53 AM EDT, 06/25/2024 (MT Newswires) -- Enovix ( ENVX ) said Tuesday it was awarded a contract from an unnamed California-based technology company to provide silicon batteries and packs for mixed reality headsets. Enovix ( ENVX ) said it will receive an immediate one-time payment for tooling to support battery pack dimensions as well as further payments for the...
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review
Jun 25, 2024
07:55 AM EDT, 06/25/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Tuesday that the US Food and Drug Administration has accepted for priority review the new drug application for its experimental drug, olezarsen, which is intended to treat adults with familial chylomicronemia syndrome, a genetic metabolic disorder. The FDA has set an action date of Dec. 19 and...
Market Chatter: Exxon Mobil-Led Consortium in Guyana Yields Net Margins Larger Than Those of Nvidia
Market Chatter: Exxon Mobil-Led Consortium in Guyana Yields Net Margins Larger Than Those of Nvidia
Jun 25, 2024
07:55 AM EDT, 06/25/2024 (MT Newswires) -- A consortium led by Exxon Mobil ( XOM )-led (XOM) in Guyana generated $6.33 billion last year, delivering a higher net margin than semiconductor maker Nvidia (NVDA), Reuters reported on Tuesday, citing Guyana government data. The net margin of Exxon's consortium was 56%, surpassing Nvidia's 49%, the report said. The Stabroek offshore venture's...
Market Chatter: Toyota Sells $2 billion Worth of Cross Shareholdings
Market Chatter: Toyota Sells $2 billion Worth of Cross Shareholdings
Jun 25, 2024
07:56 AM EDT, 06/25/2024 (MT Newswires) -- Toyota Motor ( TM ) sold $2 billion worth of cross shareholdings of listed companies in the fiscal year that ended March 31, Reuters reported Tuesday, citing its analysis of a regulatory filing. The automaker sold 325.9 billion yen ($2.04 billion) worth of such shares, reducing its stakes to 124 from 141 previously,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved